Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210288 | 0.83 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EEGFRALOX15 | |
| SCHEMBL2759445 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EEGFRALOX15 | |
| SCHEMBL2554483 | 0.79 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4EEGFRALOX15 | |
| SCHEMBL207842 | 0.77 | KDM4E (0.73) | ALDH1A1SMN1; SMN2KDM4EALOX15USP2 | |
| SCHEMBL13270161 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EEGFRPOLB | |
| SCHEMBL15330725 | 0.73 | L3MBTL1 (0.50) | ALDH1A1SMN1; SMN2KDM4EEGFRALOX15 | |
| SCHEMBL17833337 | 0.73 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL1896996 | 0.72 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL16152464 | 0.72 | CHRM2 (0.42) | ALDH1A1SMN1; SMN2KDM4EEGFRMEN1 | |
| SCHEMBL209226 | 0.71 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2EGFRGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | ALDH1A1 3015/4885SMN1; SMN2 3132/4885KDM4E 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.